CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by ...
Please provide your email address to receive an email when new articles are posted on . The AMALFI trial evaluated a completely remote approach to atrial fibrillation screening. Remote screening with ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug ...
MADRID — A simple home-based screening strategy that involved wearing an ECG patch for 14 days increased the diagnosis of atrial fibrillation (AF) and associated use of anticoagulants in patients at ...
MADRID, Spain—The use of a noninvasive ECG patch modestly increases the detection of atrial fibrillation (AF) and treatment with anticoagulant therapy among patients at moderate to high risk for ...
(RTTNews) - Tempus AI, Inc (TEM), Wednesday announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration for its Tempus ECF-AF, which utilizes AI to detect ...
A mail-based atrial fibrillation (AF) screening programme with ECG-patch monitoring led to a modest long-term increase in AF diagnosis and anticoagulation exposure in older patients at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results